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Abstract: Viral hepatitis-induced cirrhosis can progress to decompensated cirrhosis. Clinical 
decompensation represents a milestone event for the patient with cirrhosis, yet there remains 
uncertainty regarding precisely how to define this important phenomenon. With the development 
of broader treatment options for cirrhotic hepatitis patients, efficient identification of liver status 
before evolving to decompensated cirrhosis could be life-saving, but research on the topic has 
been limited by inconsistencies across studies, populations, and case-confirmation methods. We 
sought to determine whether diagnosis/procedure codes drawn from electronic health records 
(EHRs) could be used to identify patients with decompensated cirrhosis. In our first step, chart 
review was used to determine liver status (compensated cirrhosis, decompensated cirrhosis, non-
cirrhotic) in patients from the Chronic Hepatitis Cohort Study. Next, a hybrid approach between 
Least Absolute Shrinkage and Selection Operator regression and Classification Regression Trees 
models was used to optimize EHR-based identification of decompensated cirrhosis, based on 
41 diagnosis and procedure codes. These models were validated using tenfold cross-validation; 
method accuracy was evaluated by positive predictive values (PPVs) and area under receiver 
operating characteristic (AUROC) curves. Among 296 patients (23 with hepatitis B, 268 with 
hepatitis C, and 5 co-infected) with a 2:1 ratio of biopsy-confirmed cirrhosis to noncirrhosis, 
chart review identified 127 cases of decompensated cirrhosis (Kappa=0.88). The algorithm of 
five liver-related conditions—liver transplant, hepatocellular carcinoma, esophageal varices 
complications/procedures, ascites, and  cirrhosis—yielded a PPV of 85% and an AUROC of 
92%. A hierarchical subset of three conditions (hepatocellular carcinoma, ascites, and esophageal 
varices) demonstrated a PPV of 81% and an AUROC of 86%. Given the excellent predictive 
ability of our model, this EHR-based automated algorithm may be used to successfully identify 
patients with decompensated cirrhosis. This algorithm may contribute to timely identification and 
treatment of viral hepatitis patients who have progressed to decompensated cirrhosis.
Keywords: chronic viral hepatitis, hepatitis B, HBV, hepatitis C, HCV, classification and regres-
sion tree modeling, CART modeling
Introduction
Complications of liver cirrhosis include an increased risk of hepatocellular carcinoma 
(HCC), liver transplant, and death from liver failure.1–3 In “compensated” cirrhosis, 
the damaged liver still functions adequately; cirrhosis that has progressed sufficiently 
to interfere with essential bodily functions is classified as “decompensated”. The 
development of clinical decompensation represents a milestone event for the patient 
with cirrhosis, and is associated with increased morbidity, mortality, and utilization of 
Correspondence: Mei Lu
Department of Public Health Sciences, 
Henry Ford Health System, 3E One Ford 
Place, Detroit, MI, USA
Tel +1 313 874 6413
Fax +1 313 874 6730
Email mlu1@hfhs.org
Journal name: Clinical Epidemiology
Article Designation: ORIGINAL RESEARCH
Year: 2017
Volume: 9
Running head verso: Lu et al
Running head recto: EHR-based algorithm to identify decompensated cirrhosis
DOI: http://dx.doi.org/10.2147/CLEP.S136134
Clinical Epidemiology 2017:9submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
370
Lu et al
health care resources—yet there remains uncertainty regard-
ing precisely how to define this important phenomenon.
Although liver biopsy is considered the gold standard 
for confirming the presence of cirrhosis, it cannot be used 
to determine hepatic functional status.4,5 Measurement of 
hepatic venous pressure gradient has been shown to be an 
excellent predictor of stage of fibrosis and risk for decom-
pensated cirrhosis (DC), but the procedure carries risks and 
is not commonly performed in clinical practice. While the 
Child-Pugh classification stages severity of cirrhosis and 
the Model for End-Stage Liver Disease (MELD)  scores 
predict survival in a patient with cirrhosis, there remains 
considerable ambiguity regarding whether a cirrhotic 
patient has experienced decompensation.6 Signs and symp-
toms (including past or present ascites, encephalopathy, 
and even gastrointestinal bleeding) represent continuums 
that may be variously interpreted. In clinical trials, for 
example, decompensated cirrhotics are categorized as 
distinct cohorts. An efficient system to identify decompen-
sated patients from administrative data may inform early-
intervention clinical trials or epidemiological research to 
reduce poor outcomes.
Epidemiological, outcome, and economic studies of 
viral hepatitis often rely on International Classification of 
Diseases, 9th (or 10th) Revision (ICD-9/10) and Current 
Procedural Terminology (CPT) codes obtained from admin-
istrative, claims, or electronic health record (EHR) databases 
to identify patients with cirrhosis and decompensation.3,7,8 
However, diagnostic and procedure code data are subject to 
limitations, including coding inaccuracy and incompleteness. 
Several studies have been performed in United States Veter-
ans Administration populations1,9,10 to evaluate the validity 
of diagnosis codes for identification of cirrhosis/DC (alone 
or in combination with laboratory markers); however, these 
studies were limited by use of a restricted patient population, 
inconsistent results, or a focus on risk factors associated with 
DC rather than disease classification. A more recent study 
in a civilian population validated a model for identifying 
cirrhosis (a classification study) based on diagnosis codes 
and laboratory abnormalities.11 However, the outcome in 
this study was “cirrhosis”, not specifically decompensation; 
likewise, laboratory values are not typically available in 
administrative and claims databases (for example, EHR data). 
Therefore, we sought to develop and optimize a model based 
exclusively on electronic data-derived ICD-9 and CPT codes 
to accurately identify patients with DC in a civilian cohort 
of viral hepatitis patients.
Materials and methods
Study design
Our sample was drawn from a subset of hepatitis patients 
from the Chronic Hepatitis Cohort Study (CHeCS), an 
observational study of patients from four large US health 
care systems, including Henry Ford Health System (HFHS, 
Detroit, MI). The study follows all guidelines of the US 
Department of Health and Human Services regarding the 
protection of human subjects; our protocol was approved 
and renewed annually by the Institutional Review Boards 
of HFHS; Geisinger Health System; Kaiser Permanente 
Northwest; and Kaiser Permanente Hawai’i. Due to the de-
identified nature of this observational study, requirements 
for written informed consent were waived. Patient data 
were anonymized and de-identified prior to analysis. HFHS 
CHeCS patients were considered for study inclusion if they 
had biopsy-confirmed or excluded cirrhosis and clinical 
encounters data collected through the earlier date of liver 
transplant (if applicable) or December 31, 2010. In patients 
with multiple biopsies, the most severe biopsy stage was used. 
A random sample of 296 patients with a 2:1 ratio of cirrhosis 
and noncirrhosis was selected using SAS.12 Harrell’s 1-to-10 
rule of thumb13 was used to estimate sample size; assuming 
that 50% of cirrhosis cases were decompensated, up to 10 
binary/continuous predictors for multivariable modeling 
could be analyzed without overfitting the data.
Chart reviews were performed to classify the patients into 
one of three categories: 1) noncirrhotic (NC); 2) compen-
sated cirrhotic (CC); and 3) decompensated cirrhotic (DC). 
To ensure consistency, a senior hepatologist (SG) provided 
standard diagnosis guidelines and two gastroenterology fel-
lows (“raters”) performed the chart reviews. Confirmation of 
at least one of the following conditions during chart review 
resulted in a diagnosis of DC: hepatic encephalopathy; gastro-
intestinal bleeding due to portal hypertension; jaundice with 
a total bilirubin of >2.5 mg/dL; ascites/hydrothorax due to 
portal hypertension; or HCC. The two raters independently 
reviewed all patient charts. Weighted kappa (κ) was used to 
measure the agreement between the raters, accounting for the 
ordinal property of cirrhosis levels, where κ >0.80 indicates 
“excellent” agreement. Any discrepancies in classification 
between the raters were reviewed by the senior hepatologist 
for adjudication. Final clinical classification of DC versus 
compensated cirrhosis (CC) or noncirrhosis was used as the 
outcome of interest.
We hypothesized that a set of diagnosis and procedure 
codes could identify DC. To begin, we modified a set of 41 
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ICD-9 and CPT codes previously used by Spradling et al7 to 
identify cirrhotic status. These codes were grouped into ten 
clusters related to clinical presentation of hepatic decompensa-
tion (Table 1). The data collected from each cluster were either 
quantitative (counts) or categorical (presence/absence). In the 
previous study,7 a three-level cirrhosis classification variable 
(NC, CC, and DC) was derived from ten disease conditions 
(clusters). The variable was defined as “NC” if no ICD-9/CPT 
codes occurred in any of the C1–10 cluster categories, as “CC” 
if any codes from the C10 cluster were present and codes from 
the C1–C9 clusters were absent, and as “DC” if any codes 
from the C1–C9 clusters were present. We first validated this 
three-level cirrhosis classification variable, then developed 
and optimized models to predict DC based on the individual 
C1–C10 cluster variables for greater accuracy.
Statistical analysis
Descriptive statistics were used to summarize characteristics 
of the study population. Mean and standard deviation were 
used for continuous variables; frequency and percentage 
were used for categorical variables. Two novel classifiers 
were considered for the classification of DC; the first was 
logistic regression using the Least Absolute Shrinkage and 
Selection Operator (LASSO)14 approach for variable  selection 
that yields a variable combination with optimal model pre-
dictive ability. The second model used Classification and 
Regression Trees (CART),15,16 a nonparametric approach that 
generates a binary recursive multilevel tree that partitions the 
variables most predictive of the outcome of interest (in this 
case, DC).14 The CART method is ideally suited for clinical 
decision making because it can reveal important relationships 
between variables that may remain hidden when using logistic 
regression.15,16 Finally, a hybrid method between generalized 
LASSO and CART was used to simplify the model for clinical 
interpretation without loss of generalizability and accuracy.
Model learning and testing were performed based on 
the sample of 296 patients. Tenfold cross-validation was 
performed and model predictive accuracy was based on 
validation results. Predictive accuracy of the model was 
assessed using area under receiver operating characteris-
tic (AUROC) curves, as well as positive predictive value 
(PPV), sensitivity, and specificity. Models are considered 
to have “reasonable” to “excellent” predictive ability when 
the AUROC is 70%–80% and 80%–90%, respectively. The 
nonparametric Mann–Whitney approach17 was used to com-
pare the difference in AUROC between models. All analyses 
were performed using SPM version 8.0 (Salford Predictive 
Modeler)14 and SAS version 9.4.12
Table 1 ICD-9/10 and CPT codes comprising the 10 cluster variables (C1–C10)
Condition Associated ICD-9 and CPT codes Associated ICD-9/10 and CPT codes
C1: Liver transplant V42.7, 996.82, 050.5, 050.51, 050.59, 
47135, 47136
V42.7, 996.82, 050.5, 050.51, 050.59, 47135, 
47136,T86.40, T86.41, T86.42, 0FY00Z0, 0FY00Z1, 
0FY00Z2
C2: Liver cancer 155.0, 155.1, 155.2 155.0, 155.1, 155.2, C22.0, C22.2, C22.7, C22.8, C22.1, 
C22.9
C3: Hepatorenal syndrome 572.4 572.4, K76.7
C4: Hepatic encephalopathy 572.2 572.2, K72.09, K72.91
C5: Portal hypertension/portal 
decompression procedures
572.3, 37140, 37160, 37180, 37181 
37182, 37183
572.3, 37140, 37160, 37180, 37181, 37182, 37183, K76.6
C6: Esophageal varices complications 
(bleeding) and procedures
456.0, 456.20, 43204, 43205, 43243, 
43244, 43400, 43401, 42.91, 44.91, 
96.06
456.0, 456.20, 42.91, 44.91, 96.06, 43204, 43205, 43243, 
43244, 43400, 43401, I85.01, I85.11, 06L30CZ, 06L30DZ, 
06L30ZZ, 06L33CZ, 06L33DZ, 06L33ZZ, 06L34CZ, 
06L34DZ, 06L34ZZ, 06L20ZZ, 06L23ZZ, 06L24ZZ, 
0DL57DZ, 0DL58DZ 
C7: Other gastrointestinal hemorrhage 530.7, 530.82, 578.0, 578.1, 578.9 530.7, 530.82, 578.0, 578.1, 578.9, K22.6, K22.8, K92.0, 
K92.1, K92.2
C8: Ascites/paracentesis procedures 789.5, 789.59, 49080, 49081, 54.91 789.5, 789.59, 54.91, 49080, 49081, R18.8, 0D9S30Z, 
0D9S3ZZ, 0D9S40Z, 0D9S4ZZ, 0D9T30Z, 0D9T3ZZ, 
0D9T40Z, 0D9T4ZZ, 0D9V30Z, 0D9V3ZZ, 0D9V40Z, 
0D9V4ZZ, 0D9W30Z, 0D9W3ZZ, 0D9W40Z, 
0D9W4ZZ, 0W9F30Z, 0W9F3ZZ, 0W9F40Z, 
0W9F4ZZ, 0W9G30Z, 0W9G3ZZ, 0W9G40Z, 
0W9G4ZZ, 0W9J30Z, 0W9J3ZZ
C9: Other sequelae of chronic liver disease 572.8 572.8, K72.10, K72.90
C10: Cirrhosis 571.2, 571.5 571.2, 571.5, K70.30, K74.0, K74.60, K74.69
Abbreviations: CPT, Current Procedural Terminology; ICD, International Classification of Diseases.
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Given the ongoing implementation of ICD version 10, 
we conducted an ad hoc analysis based on both ICD-9 and 
ICD-10 liver-related diagnosis and procedure code data col-
lected from 01/01/2015 to 10/01/2015, and compared C1–10 
cluster variables as defined by both ICD-9 and ICD-9/10 
codes. The detailed cluster variables with related ICD-10 
codes are illustrated in Table 1.
Results
Demographic characteristics are presented in Table 2. Two 
physician raters completed independent chart reviews to clas-
sify 296 patients (23 hepatitis B virus [HBV] infected, 268 
hepatitis C virus [HCV] infected, and 5 co-infected). Agree-
ment between our two raters was “excellent” (κ=0.88; 95% 
Confidence Interval (CI): 0.84–0.92), indicating consistent 
and reliable classification assessment.18 Eighteen inconsistent 
classifications were further reviewed by the senior hepatolo-
gist (SG). Based on this chart review, 102 (34%) patients did 
not have cirrhosis, 67 (23%) had CC, and 127 (42%) had 
DC. The previously defined three-level cirrhosis classifica-
tion variable resulted in an AUROC of 80%, PPV of 70%, 
sensitivity of 90%, and specificity of 70% (data not shown). 
LASSO model
The inclusion of the full set (C1–C10) of ICD-9 variable 
clusters in the initial multivariate logistic LASSO regres-
sion model resulted in five retained clusters (C1, C2, C6, 
C8, and C10). Based on this model, the likelihood of DC 
can be predicted by a linear combination of the five cluster 
indicators: −1.52+0.98×C1+1.17×C2+0.98×C6+1.25×C8+
0.48×C10. Tenfold cross-validation estimated an AUROC 
of 89%, PPV of 83%, sensitivity of 83%, and specificity 
of 88%, using an optimized cutoff of 2.28 (Table 3A). The 
same predictive ability was observed when the cluster vari-
ables were quantitative (counts) or categorical (presence/
absence).
For clinical applications, we then developed a single, 
simplif ied f ive-cluster indicator combination model, 
Z
1
=C1+C2+C6+C8+C10, with Z
1
 ranging from 0 to 5, where 
higher scores indicate a greater likelihood of DC. The overall 
prediction accuracy (AUROC) remained similar, at 90% 
with tenfold validation (Table 3B). There was no difference 
between the AUROCs of the original and simplified models 
(p=0.09).
CART model
CART analysis generated a recursive tree with three cluster 
indicator variables (C2, C6, C8) and four terminal nodes (TN) 
(Figure 1). The AUROC was 86.8% using the learning data 
and 85.8% using the testing data (ten-fold validation). As 
illustrated in Figure 1, presence of HCC (C2) first identified 
94 patients as decompensated (TN4, with 20 misclassified, 
21%); patients without HCC would be identified as decom-
pensated if there was indication of ascites (C8; n=35 in TN3 
with 5 misclassified, 14%); patients without either HCC or 
ascites would be identified as decompensated if they had 
bleeding esophageal varices (C6; n=6 in TN2, with no mis-
classifications); PPV, sensitivity, and specificity were 81%, 
87%, and 85%, respectively, for both the learning data and 
testing data (Table 3C). Notably, the three cluster variables 
Table 2 Study population characteristics
Characteristic N=296
Age (mean, standard deviation) 58.6 (8.3)
Age category, (n)
30≤40 years 4 (1%)
41≤50 years 27 (9%)
51≤60 years 161 (54%)
61≤70 years 75 (25%)
>70 years 29 (10%)
Male sex, (n) 175 (59%)
Race, (n)
Asian/Pacific Islander 16 (5%)
White 162 (55%)
Black 108 (37%)
Native American 4 (1%)
Unknown 6 (2%)
Hispanic ethnicity, (n) 9 (3%)
Median annual household income,a (n)
<$15,000 6 (2%)
$15,000<$30,000 49 (17%)
$30,000<$50,000 106 (36%)
$50,000<$75,000 79 (27%)
≥$75,000 47 (16%)
Missing 9 (3%)
Insurance status, (n)
Medicaid 20 (7%)
Medicare 133 (45%)
Private 139 (47%)
None 4 (1%)
Unknown 334 (3%)
Liver conditions, (n)
C1: Liver transplant 54 (18%)
C2: Liver cancer 94 (32%)
C3: Hepatorenal syndrome 11 (4%)
C4: Hepatic encephalopathy 30 (10%)
C5: Portal hypertension/ portal decompression 
procedures 
25 (8%)
C6: Esophageal varices complications (bleeding) and 
procedures
24 (8%)
C7: Other gastrointestinal hemorrhage 53 (18%)
C8: Ascites/paracentesis procedures 65 (22%)
C9: Other sequelae of chronic liver disease 21 (7%)
C10: Cirrhosis 203 (67%)
Notes: aCurrency is US$.
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Table 3 Classification models for identification of DC
(A) Optimized LASSO (B) Five-cluster 
LASSO
(C) Three-cluster 
CART
(D) Five-cluster Hybrid 
Model
−1.52+0.98×C1+1.17×C2+ 
0.98×C6+1.25×C8+0.48×C10
C1+C2+C6+C8+C10  
(with all 
coefficients=1)
C2, C6, C8 (Figure 1) Combined LASSO/CART ≥2 
of C1, C2, C6, C8, and C10  
(Figure 2)
Cutoff 2.28 1.77 2
Actual 
class
Non- 
DC
DC Correct Non-
DC
DC Correct Non-
DC
DC Correct Non- 
DC
DC Correct
Testing data/model validation
Non-DC 169 148 21 88% 145 24 86% 144 25 85% 145 24 86%
DC 127 21 106 83% 23 104 82% 17 110 87% 19 108 85%
Total 296 169 127 168 128 161 135 164 132
AUROC 89% 90% 86% 86%
Specificity 88% 86% 85% 86%
Sensitivity 83% 82% 87% 85%
PPV 83% 81% 81% 82%
Learning Data/ Model Development
Non-DC 169 151 18 89% 145 24 86% 143 26 85% 145 24 86%
DC 127 21 106 83% 19 108 85% 17 110 87% 19 108 85%
Total 296 172 124  164 132  160 136  164 132  
AUROC 92% 90% 87% 85%
Specificity 89% 86% 85% 86%
Sensitivity 83% 85% 87% 85%
PPV 85% 82% 81% 82%
Abbreviations: C1, liver transplant; C2, liver cancer; C6, esophageal varices complications (bleeding) and procedures; C8, ascites/paracentesis procedures; C10, cirrhosis; 
AUROC, area under receiver operating characteristic; CART, Classification and Regression Trees; DC, decompensated cirrhosis; LASSO, Least Absolute Shrinkage and 
Selection Operator; PPV, positive predictive value.
Figure 1 The three cluster-variable CART model.
Abbreviations: C1, liver transplant; C2, liver cancer; C6, esophageal varices complications (bleeding) and procedures; C8, ascites/paracentesis procedures; C10, cirrhosis; 
CART, Classification and Regression Trees; DC, decompensated cirrhosis; TN, terminal node.
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included in the final CART model were also identified in the 
LASSO regression model.
By using the CART approach with the simplified five-
cluster combination variable (Z
1
) added to the ten cluster 
indicators (a hybrid method between LASSO and CART), 
only Z
1
 remained in the final CART model (Figure 2). A 
cutoff value of Z
1
≥2 (indicating presence of codes from two 
or more of the five cluster variables) had a validated AUROC 
of 86%, PPV of 82%, sensitivity of 85%, and specificity of 
86% (Table 3D).
In addition, a total of 2177 patients (1982 HCV, 116 
HBV, and 18 HBV/HCV coinfected) were considered who 
had at least one of the C1–C10-related diagnosis codes 
from 01/01/2015 to 10/01/2016. Of them, 125 patients had 
C1–C10-related ICD-10 diagnosis and procedures. There 
was complete concordance between ICD-9 and ICD-9/10 
classifications for all patients except one, who presented with 
C2 (HCC)-related ICD-10 codes.
Discussion
In clinical practice, the terms “decompensatd cirrhosis” and 
“end-stage liver disease” lack precise definitions. Moreover, 
patients with cirrhosis may experience “episodes of decom-
pensation”, such as transient ascites formation, and then 
revert back to a fully compensated state once ascites resolves. 
Similar events of variceal bleeding or hepatic encephalopathy, 
for example, may represent transient phenomena. With the 
advent of newer direct-acting all-oral (DAA) treatments for 
HCV, it is especially important to have consensus regarding 
this clinically important condition, because treatment options 
may vary if a cirrhotic patient has ever experienced “decom-
pensation”. For example, the US Food and Drug Administra-
tion recently issued a warning regarding the use of protease 
inhibitor antiviral therapy in chronic HCV patients who have 
ever experienced hepatic decompensation.
Our method—based on EHR-based diagnosis and pro-
cedure codes—may provide both clinicians and researchers 
an efficient and accurate method for the identification of 
decompensation among patients with viral hepatitis. Due 
to the low accuracy of individual diagnosis codes in detect-
ing DC,7 we grouped these codes into clusters of diagnoses 
related to specific manifestations of decompensation. We 
first validated a previously defined three-level classifica-
tion variable based on ten clusters of 41 ICD-9 and CPT 
codes. We then developed an optimal algorithm based on 
the individual C1–C10 cluster variables for greater predic-
tive ability.
To ensure the reliability of our classification of DC, medical 
records were reviewed by two trained raters and discrepancies 
were adjudicated by an expert hepatologist; agreement between 
the reviewers was “excellent” (κ=0.88; 95% CI: 0.84–0.92), 
indicating high reliability. Our results showed that the predic-
tive ability of the previously defined three-level cirrhosis clas-
sification variable (from 41 diagnosis and procedure codes) 
was “excellent” (AUROC=80%), although specificity was 
only “moderate” (70%), indicating a high false-positive rate.
The parametric LASSO regression model (−1.52+0.98×C1+
1.17×C2+0.98×C6+1.25×C8+0.48×C10; Table 3A), based on 
five cluster variables derived from 27 individual diagnosis and 
procedure codes, demonstrated the likelihood (probability) of 
decompensation on a continuous scale. The model’s predictive 
ability was in the upper range of “excellent” (AUROC=89%; 
PPV=83%). The simplified LASSO regression model (Table 
3B) using a coefficient of 1 for all five cluster variables 
(Z
1
=C1+C2+C6+C8+C10) retained similar identification 
accuracy (AUROC=86%; PPV=82%). Notably, the nonpara-
metric CART model ended with the same five cluster variables 
(Table 3C) obtained from the LASSO model, which indicates 
robustness of the DC identification process.
The classification model using a hybrid LASSO/CART 
approach with a cutoff of Z
1
≥2 (Table 3D) retained similar 
identification accuracy (AUROC=86%; PPV=82%). Cir-
rhotic patients would be classified as “decompensated” if 
they ever had one of the following four conditions—liver 
transplant, HCC, complications or procedures related to 
esophageal varices, or ascites. This model may be more useful 
in a clinical setting or for researchers.
The abbreviated three-cluster variable model (derived 
from 17 individual diagnosis and procedure codes) identified 
DC (Figure 1) with only slightly reduced predictive accuracy 
(AUROC=86%; PPV=81%). Patients would be classified as 
“decompensated” at Level 1 in the presence of HCC-related 
Figure 2 The hybrid CART model.
Abbreviations: C1, liver transplant; C2, liver cancer; C6, esophageal varices, 
complications (bleeding), and procedures; C8, ascites/paracentesis procedures; 
CART, Classification and Regression Trees; DC, decompensated cirrhosis; TN, 
terminal node.
Initial cohort
Class
DC
Non-DC
n
127
296
169
%
43
57
C1+C2+C6+C8+C10<2
Class
DC
Non-DC
n
19
(TN1) 164
145
%
12
88
C1+C2+C6+C8+C10≥2
Class
DC
Non-DC
n
108
(TN2) 132
24
%
82
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codes (C2); at Level 2 in the absence of HCC-related codes, 
but in the presence of ascites-related codes (C8); and at 
Level 3 in the absence of HCC- and ascites-related codes, 
but in the presence of codes related to bleeding esophageal 
varices (C6). The agreement between the hybrid five-cluster 
variable model with Z
1
≥2 as the cutoff and the CART 
three-cluster models was “outstanding” (κ=0.93; 95% CI: 
0.88–0.97). This simplified model would be easy to use in 
clinical practice: cirrhotic patients may reliably be considered 
“ever decompensated” if they have one of the following four 
conditions in their medical records—liver transplant, HCC, 
complications or procedures related to esophageal varices, 
or ascites.
We note that our sample included only patients with 
chronic viral hepatitis. However, diagnosis and procedure 
codes related to viral hepatitis were not included in the 
model and, thus, were not relevant to its accuracy. Likewise, 
the conditions that define cirrhotic decompensation are the 
same regardless of etiology. This algorithm also requires fur-
ther validation in an independent cohort with similar patient 
characteristics, as well as among patients with other causes 
of liver disease.
Our ad hoc analysis showed that ICD-10 codes enrich 
ICD-9 codes. In CART models using either the cutoff 
value of 1.77 or ≥2 C1–C10 clusters, we conclude that our 
ICD-9–based CART model could be adapted and replaced 
with ICD-9/10 codes.
In conclusion, our study showed that the presence of 
diagnosis and procedure codes in patient records could be 
used to efficiently identify patients with DC. We expect the 
results of this study to be useful for epidemiological and 
economic research of viral hepatitis-related liver disease, 
as well as serve as a quality improvement tool to ensure the 
best available care for such patients. Our algorithm may also 
be useful in the identification of risk factors for decompen-
sation in observational studies with large cohorts of viral 
hepatitis patients. There are now effective therapies that may 
be life-saving for cirrhotic patients before or even after their 
condition worsens6 —this tool may help clinicians recognize 
that cirrhosis has evolved to the point of decompensation. 
Our algorithm could be applied to electronic medical record 
systems to trigger automated alerts for specialty referrals; 
such alerts may contribute to timely clinical management 
of cirrhosis and its complications.
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